Traditional or de novo drug discovery is a time-consuming, costly, and high-investment process due to the high attrition rate. Therefore, many trials are conducted to reuse existing drugs to treat pressing conditions and diseases, since their safety profiles and pharmacokinetics are already available. Drug repurposing (DR) (also known as drug repositioning) is a strategy to identify a new indication of existing or already-approved drugs, beyond the scope of their original use. Various in silico-based computational and activity-based experimental approaches to incorporate available resources have been suggested for gaining a better understanding of disease mechanisms and the identification of repurposed drug candidates for personalized pharmacotherapy. This strategy is highly efficient, timesaving, low-cost, and minimum risk of failure. It maximizes the therapeutic value of a drug and consequently increases the success rate. This review introduced publicly available databases for drug repositioning and summarized the approaches taken for drug repositioning. Also, it highlighted and compared their characteristics, which should be addressed for the future realization of drug repositioning.
Nossier, Eman S., Anwar, Manal M., El-Zahabi, Mohamed Ayman. Recent advances in drug repositioning and rediscovery for different therapeutic activities utilizing updated technological approaches. // Molecular Diversity. – 2026. – DOI: 10.1007/s11030-025-11248-w. – URL: http://link.springer.com/openurl/fulltext?id=doi:10.1007/s11030-025-11248-w
Nossier, Eman S, Anwar, Manal M, El-Zahabi, & Mohamed Ayman (2026). Recent advances in drug repositioning and rediscovery for different therapeutic activities utilizing updated technological approaches. Molecular Diversity. https://doi.org/10.1007/s11030-025-11248-w
Nossier, et al. “Recent advances in drug repositioning and rediscovery for different therapeutic activities utilizing updated technological approaches.” Molecular Diversity, 2026. doi:10.1007/s11030-025-11248-w.
@article{Nossier2026,
title = {Recent advances in drug repositioning and rediscovery for different therapeutic activities utilizing updated technological approaches},
author = {Nossier and S., Eman and Anwar and M., Manal and El-Zahabi and Ayman, Mohamed},
journal = {Molecular Diversity},
year = {2026},
doi = {10.1007/s11030-025-11248-w},
url = {http://link.springer.com/openurl/fulltext?id=doi:10.1007/s11030-025-11248-w}
}
Large extracellular vesicles (lEVs) are heterogeneous structures with sizes that exceed 200 nm. Unlike small extracellular vesicles, which originate from either the endosomal system or the plasma membrane, most lEVs stem directly from...
Chaperone-mediated autophagy (CMA), the first-described selective lysosomal degradation pathway, is distinguished from other degradative pathways by the unique mechanism by which substrates reach the lysosomal lumen: CMA relies on a...
This Review focuses on the choice between homologous recombination and non-homologous end joining in DNA double-strand break repair. The antagonistic roles of 53BP1 and BRCA1–BARD1, the contribution of RNA–DNA hybrids and implications...
A 2010 paper identified PRDM9 as the sequence-specific regulator of meiotic recombination hotspots, showing it co-evolves with its rapidly changing binding motifs.
Genome editing is maturing from a one-size-fits-all system into a highly specialized ecosystem that includes a dizzying array of tools. In this Comment, we discuss the current and future use of Cas-induced homology-directed repair for...